ArticleBMC infectious diseases2025
Treatment outcomes and associated influencing factors among elderly patients with rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study in China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Epidemiological Characteristics and Spatiotemporal Cluster Analysis of Multidrug-Resistant and Rifampicin-Resistant Tuberculosis Among Older People - China, 2019-2025.China CDC weekly · 2026Article
- Effects of a family collaboration care model on disease perception, self-management, and quality of life in elderly patients with multidrug-resistant pulmonary tuberculosis: a retrospective study.Frontiers in medicine · 2026Article
- Clinical and Microbiological Characteristics Associated with Treatment Outcomes Among Rifampicin-Resistant Tuberculosis Patients in Limpopo Province.Infection and drug resistance · 2026Article
- Effect of Drug Cost-Exemption Policy on Treatment Outcomes in Multidrug-Resistant Tuberculosis Patients in Guangxi Zhuang Autonomous Region, China: A Nested Case-Control Study.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Severe pre-treatment attrition in the care cascade: clinical outcomes and risk factors among older MDR/RR-TB patients in China.Frontiers in public health · 2026Article
- Congenital tuberculosis in preterm infants in a high-burden setting in southwest China: a single-center cross-sectional study.Frontiers in pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundRifampicin-resistant tuberculosis (RR-TB) remains a significant global public health concern. The elderly population is not only at high risk and among the primary victims of RR-TB but also plays a crucial role in the transmission chain of RR-TB. Their biological particularities, treatment complexities, and social vulnerabilities collectively present substantial challenges to global tuberculosis control. This study aimed to evaluate treatment outcomes and identify predictors of unfavorable outcomes among elderly patients with RR-TB in China.
methodsA multicenter retrospective cohort study was conducted, including 248 elderly RR-TB patients treated across eight tertiary hospitals in China from May 2018 to April 2020. Multivariate logistic regression and Propensity Score Matching (PSM) analyses were performed to identify factors associated with unfavorable outcomes. Statistical analyses were performed using SPSS.
resultsAmong 248 patients, 65.7% (163/248) achieved treatment success (cured or completed treatment), while 34.3% (85/248) experienced unfavorable outcomes, including treatment failure (10.5%), death (2.4%), loss to follow-up (15.7%), and non-evaluation (5.6%). Adverse events (AEs) were reported in 56.0% (139/248) of patients, among which anemia was the most common (25.8%). And the use of bedaquiline and linezolid was significantly associated with the occurrence of QT interval prolongation and optic neuritis (p < 0.05). Multivariate analysis revealed that BMI < 18.5 kg/m²(aOR: 3.66, 95% CI: 1.89-7.08, p < 0.01), advanced drug resistance (aOR: 2.25, 95% CI: 1.14-4.45, p = 0.020), pre-treatment anemia (aOR: 4.16, 95% CI: 2.01-8.61, p < 0.001) were independent predictors of unfavorable outcomes. Adjunctive immunotherapy was associated with favorable outcomes (aOR: 0.23, 95% CI: 0.09-0.55, p < 0.001). After PSM, pre-treatment anemia remained significantly correlated with unfavorable outcomes (aOR: 3.5; 95% CI: 1.41-8.67, p = 0.007).
conclusionA relatively low rates of treatment success were achieved for RR-TB patients in the elderly at tertiary tuberculosis hospitals in China. Low BMI, advanced drug resistance, and pre-treatment anemia were independent prognostic factors for unfavorable treatment outcomes. Adjunctive immunotherapy was prognostic factors for unfavorable treatment outcomes of elderly RR-TB patients. In tuberculosis management, special consideration should be given to elderly patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.